The Finincial Times
Lykos said on Thursday that Doblin had left its board as it announced plans to cut around three-quarters of its workforce while retaining staff working on clinical development and regulatory affairs. His exit comes a decade after the company was spun out of the non-profit Multidisciplinary Association for Psychedelic Studies (Maps), which Doblin founded in 1986, and comes as Lykos tries to secure approval for the first new PTSD treatment in more than two decades. “I can speak more freely as a public advocate by resigning from the Lykos board,” said Doblin, who will remain involved with Maps, which is Lykos’s biggest shareholder and philanthropically funded its trials. He added that he was “deeply saddened” by the FDA’s decision but “heartened” by Lykos’s continued push to get MDMA approved.
Read full story
https://www.ft.com/content/fe21d226-6e1d-4d61-89e1-f62837e3d5eb
